We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Machine-Learning Algorithm Analyzes Images to Identify Schizophrenia Patients

By HospiMedica International staff writers
Posted on 31 Jul 2018
A team of researchers from the University of Alberta (Edmonton, Alberta, Canada) has developed a machine-learning algorithm to examine functional magnetic resonance imaging (fMRI) images for identifying patients suffering from schizophrenia and ascertaining if they would respond to treatment. More...
In a study, the algorithm examined MRI images of both newly diagnosed, previously untreated schizophrenia patients and healthy subjects and successfully identified patients with schizophrenia at 78% accuracy. It also predicted whether or not a patient would respond positively to a specific antipsychotic treatment named risperidone with 82% accuracy.

Schizophrenia, a severe and disabling psychiatric disorder that comes with delusions, hallucinations and cognitive impairments, affects approximately one in 100 people at some point in their lives. Early diagnosis of schizophrenia and other mental disorders still remains a challenge, while clinicians face the difficult task of devising a personalized treatment strategy during the first visit with a patient. Currently, the treatment of schizophrenia is usually determined using a trial-and-error style. However, if a drug does not work properly, the patient can suffer prolonged symptoms and side effects, and miss the best time window to control and treat the disease.

The initial trial results of the machine-learning algorithm for the diagnosis and treatment of schizophrenia have been encouraging. However, further validations on large samples will be required and more refinement is needed to improve its accuracy before using it in a clinical environment. The researchers also expect to expand their work to include other mental illness such as major depressive and bipolar disorders.

"This is the first step, but ultimately we hope to find reliable biomarkers that can predict schizophrenia before the symptoms show up," said Bo Cao, an assistant professor of psychiatry at the University of Alberta, who led the research. "We also want to use machine learning to optimize a patient's treatment plan. It wouldn't replace the doctor. In the future, with the help of machine learning, if the doctor can select the best medicine or procedure for a specific patient at the first visit, it would be a good step forward."

Related Links:
University of Alberta


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
LED Surgical Lamp
ACEMST35/57
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.